A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2013
This article has no abstract
Epistemonikos ID: 199d4eff1e8a502c6ea45ea54b0dc34d7190bf73
First added on: Apr 16, 2025